ECT / Galvanisation Therapy There are nowadays several ways of destroying degenerative tissue. Established methods are: surgery, irradiation and chemotherapy. Other methods are: hyperthermia, laser, cryosurgery, BET (Bio-Electro Therapy), ECT (Electro Cancer Therapy), PET (Percutaneous Electro Tumour Therapy) and Galvanisation Therapy.

...klick on Button

The results: The tumour tissue is destroyed without damaging the surrounding, healthy body cells. The tissue sterilely destroyed in this way (aseptic necrosis) slowly separates over the following weeks from the healthy tissue and is either extruded (in cases of tumours lying on the surface) or is metabolized by the body's own phagocytes. For some time now one has made use of not only needle electrodes, but also of flat electrodes, which can be placed on the stomach and on the back for purposes of treating the internal organs. One of the areas of application for BET/ECT is therefore now also in combating prostatic cancer, in order to spare the patient the operation. Especially for a tumour that is still very small and is not associated with complaints, patients often have difficulties in opting for the large operation. The BET/ECT option can help here, in a caring way, to avoid unnecessary extensive surgery. The voltage created between the electrodes creates a galvanic current that enables almost selective destruction of the tumour tissue. This represents a new possibility for destroying tumour tissue in a more caring way. The direct current flowing between two or more electrodes results in tissue destruction by means of electrolysis. The ionic migration gives rise to a considerable change in the pH-value of the tissue. At the anode an acidic pH-value is created, whereas at the cathode the pH-value is alkaline. The pH-values thereby achieved lie far beyond the physiological spectrum and are thus tissue-damaging. The direct current also brings about a change in the membrane potential by altering the electrolytic milieu around and inside the cells. This in turn completely destroys important physiological functions, such as the sodium-potassium pump. In the electric field various salts disassociate into cations and anions, interrupting the homeostasis of the cells. Within the tissue vasodilatation occurs at the cathode, desiccation, relief from pain and anti-inflammation at the anode. This devitalizes the tumour tissue. The electrical devitalization is no typical electrical injury. It is almost always painless and does not interfere with the general feeling of wellbeing. The expulsion of the electrically induced necrosis material does not take place until weeks later. The loss in substance is size-equivalent to the original growth of the tumour tissue. The BET/ECT treatment is suitable for solid tumours or metastases both at the surface and situated deeper. Various numbers of electrodes are needed, depending on the size of the tumour. The current is transferred to the tissue via platinum electrodes. The treatment can usually be applied under local anaesthesia, since the low-level direct current depolarizes the pain receptors and the conductivity of the sensitive nerves is paralysed by the acids and bases created. The BET/ECT method also triggers an active, specific immunity phenomenon, since tumour-specific antigens are released by the galvanic current and are presented to the immune cells attracted by the current. The tissue destruction releases cytokines which in turn leads to improved recognition of the tumour antigens and the specific immunological performance of the tumour carrier. In the case of deeper-lying tumours the electrodes are positioned under visual control with the help of ultrasound. The BET/ECT approach can also be combined with anionic cytostatic agents such as adriblastin, epirubicin, cisplatin and mitomycin. These are infiltrated at the anode. The BET/ECT approach permits combination with chemotherapy, irradiation, hyperthermia, immunological and other biological therapies. Thanks to the pioneering work of Dr. Rudolf Pekar of Bad Ischl, who since the beginning of the seventies has refined the techniques of the galvano methods and, by publishing his findings – not to forget the research work carried out by Swedish, Austrian and US research teams – has put us in a position of now being able to successfully carry out oncotherapy employing galvanic current. At present the Electro Cancer Therapy is being successfully used in Germany, Austria, Denmark, Italy and China. Notable successes have already been made. It should be said in particular in this connection that the percutaneous Electro Tumour Therapy practically excludes the danger of reformation of the metastases, since it also works preventively against such reformation. These involve complex electrical procedures in the metabolism of the organism or of the cells exerting a strong effect on the bio-electrical fields. Treatment: the treatment is best-suited to solid tumours, whether surface tumours or deeper-lying, that can be reached with a needle electrode and which, for aesthetic or functional reasons, are non-operable. These include: Prostatic cancer, as recently demonstrated by a study in the University Clinic, Frankfurt, under the direction of Prof. Dr. med. Vogel. Other fields of indication include mammary carcinomas, particularly on recurrence after radiotherapy and chemotherapy, selective tumours in the area of the ears, nose and throat, skin cancer such as basilomas, spinocellular carcinomas, melanomas, etc., skin metastases, soft-tissue tumours, and isolated organ metastases. Tumours frequently lie more or less on the surface, in the area of the visceral cranium, glands, muscles , breast , lymph, arms, legs and skin, and are thereby accessible. Domestic and foreign students verify the positive effect of this no-side-effects method of combating tumours – particularly in China, where its healing record is up to 80%. The direct-current therapy was already in use at the end of the last century. This form of treatment was more or less forgotten, however, with the introduction of chemotherapy. As to the functioning of the direct-current therapy: the use of several special, electrically isolated needles makes it possible to create a field of tension that causes a depolarization of the tumour's cell membrane. The field of tension is maintained by administering a pre-specified electrical current (milliamperes/mA) within a certain period of time. Each cell has an electrical potential as an electrical environment. Each biological activity also has an electrical environment. Health and illness are thus closely bound up with electrical currents, that also form part of an electrical field. At best, classical types of tumour therapy (operation / chemotherapy / radiotherapy) eradicate the tumour, but the altered electromagnetic field is not corrected. (Theory of Local Recurrence). The remaining polarization and with it the transforming tendency of the area can provide the basis for a relapse (metastases), and would thereby explain why the curative measure achieve effect, yet leave the cause undefeated (Dr. Pekar, Austria). The application of a direct electrical current could reverse the polarity of the improper electric field and so activate the energetic flow of current in keeping with the laws of the organism as a whole, thereby inducing the self-healing process and triggering the immune system. In Europe, Dr. Nordenstroem (Sweden) and Dr. Pekar (Austria), working independently of each other since the end of the 60s, have continued to practice direct-current therapy and have further developed it for clinical application. The effective mechanisms of the direct-current therapy have not as yet been fully explained. Certain effective mechanisms at cell level have however already been scientifically confirmed by research. The effectiveness of ECT on the tumour can also be greatly improved by the injection of intra-tumour chemotherapeutic agents. The therapy employing direct current is successfully applied in many countries (China, Brazil, Italy, Denmark, Sweden and Austria). Studies. Prof. Dr. Xin YU-LING in China has treated tumour patients with direct current. For 593 patients with lung cancer he was able to record complete remission in 28.3% of the cases, partial remission in 50.3%, no remission in 12.8% and an increase in tumour size in 8.6% of the cases. For 389 patients treated for liver cancer he recorded complete remission in 25.2% of the cases and partial remission in 50.4%. Amongst this group of patients no remission was recorded in 19.0% of the cases and tumour growth in 5.1%. Complete remission means that after the treatment no tumour is detectable. Partial remission means that the tumour has been reduced in size by more than half its initial size. No remission means that the tumour has been reduced in size by less than 30% of its initial size. Xin also presents the survival periods of the patients treated with direct-current therapy. All patients with a small tumour (3-5 cm in diameter) at the outset of the therapy were still alive one year after the end of the treatment. After 5 years 70 % of these patients were still alive. For patients with locally limited tumours (stage T1N0M0 in keeping with the TNM classification of the WHO) the survival rate after 1 year was 100% and after 5 years 85%. Why this therapy is so little-used in Germany is for me, personally, a complete conundrum. top >